Physician profile
Thomas C Roberts
NPI 1922068832
$4,967.42
in general payments reported to CMS, 2019-2025
16 companies · $936 in 2025
The $936 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $155 · 2021: $466 · 2022: $894 · 2023: $872 · 2024: $768 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $16.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.30 |
| Education | $16.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,605.91 | 2019-2025 | Dalvance, Teflaro, Avycaz |
| Viiv Healthcare Company | $1,009.40 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $699.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $695.73 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Astellas Pharma US INC | $414.37 | 2019-2024 | Cresemba |
| Glaxosmithkline, LLC. | $187.90 | 2019-2025 | Shingrix, Arexvy |
| Insmed, INC. | $99.64 | 2019-2025 | Arikayce |
| La Jolla Pharmaceutical Company | $46.40 | 2025 | Zevtera |
| Ferring Pharmaceuticals INC. | $42.18 | 2023 | Rebyota |
| Janssen Biotech, INC. | $36.98 | 2021 | |
| Pfizer INC. | $33.50 | 2024 | |
| Allergan, INC. | $30.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $19.72 | 2024 | Vibativ |
| Nabriva Therapeutics, Plc | $13.45 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.